CompletedPhase 3NCT00358501

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients

Studying Hepatic veno-occlusive disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Jazz Pharmaceuticals
Principal Investigator
Paul Richardson, M.D.
Dana-Farber Cancer Institute
Intervention
Defibrotide(drug)
Enrollment
134 target
Eligibility
All sexes
Timeline
20062015

Study locations (25)

Collaborators

FDA Office of Orphan Products Development

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00358501 on ClinicalTrials.gov

Other trials for Hepatic veno-occlusive disease

Additional recruiting or active studies for the same condition.

See all trials for Hepatic veno-occlusive disease

← Back to all trials